Mayne Pharma Group Limited

ASX:MYX Stock Report

Market Cap: AU$455.0m

Mayne Pharma Group Future Growth

Future criteria checks 4/6

Mayne Pharma Group is forecast to grow earnings and revenue by 111.4% and 9.3% per annum respectively while EPS is expected to grow by 111.4% per annum.

Key information

111.4%

Earnings growth rate

111.4%

EPS growth rate

Pharmaceuticals earnings growth36.2%
Revenue growth rate9.3%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Dec 2024

Recent future growth updates

Recent updates

Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%

Feb 13
Mayne Pharma Group Limited (ASX:MYX) Held Back By Insufficient Growth Even After Shares Climb 26%

A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Sep 01
A Piece Of The Puzzle Missing From Mayne Pharma Group Limited's (ASX:MYX) 30% Share Price Climb

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Dec 03
Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Dec 01
Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Apr 12
Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01
Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16
We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10
Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17
Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22
Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01
How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08
What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18
Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27
Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Earnings and Revenue Growth Forecasts

ASX:MYX - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202752114N/AN/A1
6/30/2026457-4N/A-92
6/30/2025418-15N/A-242
6/30/2024388-169-36-15N/A
12/31/2023319-274-34-15N/A
9/30/2023251-296-148-29N/A
6/30/2023184-317-262-43N/A
12/31/202259-257-287-64N/A
9/30/2022108-233-153-36N/A
6/30/2022157-209-19-7N/A
3/31/2022250-151-133N/A
12/31/2021342-93-713N/A
9/30/2021372-1511436N/A
6/30/2021401-2083459N/A
3/31/2021420-2325682N/A
12/31/2020439-25678106N/A
9/30/2020448-17472109N/A
6/30/2020457-9365113N/A
3/31/2020467-19661109N/A
12/31/2019478-30056106N/A
9/30/2019502-29040106N/A
6/30/2019525-27925107N/A
3/31/2019543-11828117N/A
12/31/20185614331127N/A
9/30/2018546-4629124N/A
6/30/2018530-13427121N/A
3/31/2018526-146N/A111N/A
12/31/2017521-158N/A100N/A
9/30/2017547-35N/A42N/A
6/30/201757389N/A-15N/A
3/31/201750490N/A-30N/A
12/31/201643591N/A-44N/A
9/30/201635164N/A5N/A
6/30/201626737N/A54N/A
3/31/201623830N/A49N/A
12/31/201520923N/A44N/A
9/30/201517515N/A33N/A
6/30/20151418N/A22N/A
3/31/201513712N/A21N/A
12/31/201413317N/A20N/A
9/30/201413819N/A23N/A
6/30/201414321N/A26N/A
3/31/201413515N/A24N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: MYX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MYX is expected to become profitable in the next 3 years.

Revenue vs Market: MYX's revenue (9.3% per year) is forecast to grow faster than the Australian market (5.9% per year).

High Growth Revenue: MYX's revenue (9.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MYX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 08:41
End of Day Share Price 2025/02/14 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mayne Pharma Group Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William DunlopBofA Global Research
Martyn JacobsCanaccord Genuity
Elyse ShapiroCanaccord Genuity